Yeast Expression System

Yeast Expression System designates recombinant protein production platforms using yeast organisms such as Saccharomyces cerevisiae or Pichia pastoris as host cells for expressing therapeutic proteins, enzymes, vaccines, or research reagents, offering advantages including rapid growth, cost-effective fermentation, scalability, and ability to perform certain eukaryotic post-translational modifications. Yeast expression provides intermediate complexity between bacterial and mammalian platforms, enabling production of proteins requiring disulphide bond formation and secretion pathways while maintaining robust manufacturing economics.

The biopharmaceutical industry employs yeast expression systems for producing biologics including insulin, hepatitis B vaccines, and enzyme replacement therapies. Yeast platforms support high cell density fermentation achieving strong yields, with secretion of proteins simplifying downstream purification. Genetic engineering optimises expression through promoter selection, codon optimisation, gene copy number control, and strain development. However, yeast glycosylation patterns differ from human glycosylation, often producing high-mannose glycans that may affect immunogenicity or pharmacokinetics, requiring glycoengineering strategies when needed. Process development focuses on fermentation parameters balancing productivity and protein quality. As biologics demand grows and manufacturers seek flexible, scalable systems, yeast expression remains a valuable platform enabling efficient production with strong commercial feasibility and proven regulatory acceptance.